title: [Osteoporosis].
abstract: Fracture risk could be evaluated with FRAX. Vitamin D administration decreases the rate of falls and deaths. Denosumab reduces the risk of fracture in postmenopausal women with osteoporosis and shows positive effects in case of breast and prostate cancers with hormone deprivation therapies. Zoledronate and teriparatide alone are more effective than risedronate and alendronate respectively in treatment of glucocorticoids induced osteoporosis. The association zoledronate and teriparatide may be promising. Vertebroplasty is not the first line treatment for symptomatic osteoporotic vertebral fractures. Osteonecrosis of the jaw and subtrochanteric femoral fractures are still events to consider in case of treatments with bisphosphonates.
authors.affiliation: Service des maladies osseuses, Département de réhabilitation et gériatrie, HUG et Faculté de médecine de Genève, 1211 Genève 14.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Uebelhart
authors.forename: René
authors.initials: R
authors.lastname: Rizzoli
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents